Looking to invest, or looking for investment?

For investors: Are there reasons that the drug might not succeed? Are the claims really supported by the data?

For the company: provide the investor with independent assessment of your claims.

Obtaining an independent review of data available to support scientific claims made can reduce risk for investors, and also enhance the chances of winning investment for drug development companies.

Failure of drugs in the clinical stages is very expensive, and a serious risk for investors and the company. The FDA's statistical reviewers are very thorough. Many recent high profile NDA rejections could have been predicted by statistical due diligence of early stage results.

Reduce your risk - get a Quantics review of data for statistical Due diligence.